Adjacent Evidence Brief: Telomere Cancer Effects

Artifact

Living evidence brief from agent-v3-full-paper-live

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Reconcile the conclusion's breadth with the actual evidence slice: either narrow the conclusion to the bounded mechanistic/adjacent tier it actually supports, or add an explicit translation section that maps the 26 admitted sources to specific clinical/survivorship/marketing claims with appropriate hedging.
2. Resolve direction-coding inconsistencies for sources with clearly reported effect directions in the bundle excerpts (Jaeger 2024, Davidson-Swinton 2026, Sarkar 2026, Ha 2023, Sasmita 2025) and surface the dominant cross-source signal that longer genetically predicted TL is associated with increased risk of multiple neoplasms (Cheng 2026, Aierken 2026, Chen 2023, Davidson-Swinton 2026, Wan 2023, Song 2022, Andreikos 2024).
3. Include the omitted admitted sources (Langsenlehner 2026, Gil-Korilis 2026, Brown 2026, Genetta 2026, Andreikos 2024, Wan 2023, Song 2022, Chen 2023, Alqaisi 2026, Markozannes 2022, Bhat 2023, Cheng 2026, Aierken 2026, Xu 2024, Gui 2025) in the Evidence Landscape tables or justify their exclusion from the synthesis tables.
4. Fix the admission funnel arithmetic so the count categories reconcile with the final 26 admitted sources.
5. Expand Key Findings beyond the outcome-class header note to summarize the tiered interpretation the conclusion promises.

Major issues

• Conclusion is partially disconnected from the cited evidence slice: the conclusion discusses broad clinical, survivorship, and anti-aging marketing implications while almost all admitted sources (22/26) are not direct interventional hard-endpoint evidence (0/26 are classified as direct). The body itself acknowledges the corpus cannot justify the applied claims, which is correct, but the conclusion's framing around 'commercial anti-aging interventions' and 'preventive counseling' is broader than the direct evidence slice warrants.
• Several source-level direction codes in the body are misaligned with the underlying study findings. Jaeger 2024 (Astragalus RCT) shows supplement vs placebo p=0.01 for longer TL but is coded direction=unclear rather than positive. Davidson-Swinton 2026 (POT1 long telomere syndrome) shows longer TL and increased lymphoid malignancy risk (HR 8.28) but is coded direction=unclear. Sarkar 2026 (CRC LTL survival) shows significant association but coded direction=unclear. Langsenlehner 2026 (prostate radiotherapy) is omitted from the narrative despite being admitted. These direction-codings are conservative but produce a body that understates the clearest signals (longer TL → increased risk in multiple MR-based and POT1 evidence) while the conclusion warns against broader claims.

Minor issues

• The Search Summary admission funnel arithmetic is inconsistent: receipt candidate union 194 minus 74 source candidates leaves 120, but no-excludable-claims (41), none-only (8), partial-or-none (49), and partial-only (19) sum to 117, and strict high-confidence (3) plus admitted final (26) does not reconcile cleanly with the candidate counts.
• 'Receipt-level direction coded unclear' is used for many sources that have clearly reported effects in the bundle excerpts (e.g., Sasmita 2025 reports HR/OR with CIs; Ha 2023 reports no group differences). This makes the body narrative less informative than the underlying data.
• Liang 2024 is classified under Longevity but is primarily an HIV/cancer/mortality biomarker study; the Longevity framing may mislead.
• Several admitted sources (Cheng 2026, Aierken 2026, Xu 2024, Bhat 2023, Gui 2025, Brown 2026, Genetta 2026, Gil-Korilis 2026, Andreikos 2024, Wan 2023, Song 2022, Chen 2023, Alqaisi 2026, Markozannes 2022, Langsenlehner 2026) are mentioned only in the bundle and not surfaced in the Evidence Landscape tables, creating a coverage gap between the 26 admitted sources and the ~14 displayed.
• The Key Findings section is truncated to the outcome-class note and adds no substantive content beyond repeating the Evidence Landscape framing.

Reviewer note

This is a thin-corpus rapid evidence synthesis on telomere cancer effects with an explicit and well-documented search protocol, deterministic audit trail, and a defensibly bounded interpretation that direct interventional hard-endpoint evidence is absent. The search summary is unusually explicit for a rapid synthesis, the evidence-honesty framing is appropriate, and the limitations section honestly identifies evidence-role imbalance (0/26 direct sources), endpoint heterogeneity, and the conservative-numerics exclusion rule. The gaps section identifies actionable next-step needs (prespecified endpoints, standardization, separation of direct vs adjacent). The main weakness is internal alignment. The conclusion is more aspirational than the body supports, and the body's direction codings are conservative to the point of obscuring the clearest cross-source signal in the bundle: multiple MR-based and genetic-syndrome studies (Cheng 2026, Aierken 2026, Chen 2023, Davidson-Swinton 2026, Wan 2023, Song 2022, Andreikos 2024) consistently show longer telomere length associated with increased risk of multiple cancers, yet most of these are either direction-coded 'unclear' or omitted from the Evidence Landscape tables entirely. The two highest-profile signals in the bundle (POT1 long telomere syndrome with HR 8.28 for lymphoid malignancy; Astragalus RCT with significant TL lengthening) are coded direction=unclear, which is internally inconsistent with the cited statistics. This does not rise to significant overclaim in the causal/policy sense — the conclusion correctly refuses clinical recommendations — but it is enough misalignment between source evidence and coded synthesis that the manuscript needs bounded revisions. Recommendation: revise. The manuscript is salvageable with bounded edits that (a) reconcile the conclusion's scope with the actual evidence slice, (b) fix direction coding for sources with clearly reported effects, and (c) either include or explain the omission of the 10+ admitted sources not surfaced in the evidence landscape tables.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis